Trial ID 21448 | Maryland Oncology Hematology Trial ID 21448 – Maryland Oncology Hematology

Trial ID 21448

Trial Information - Phase II

A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting (G1T28-213)

Disease Specifics: (mTNBC)

Protocol ID: G1T28-213

Sponsor: G1 Therapeutics

Status: STAR TRIAL

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast

Status

STAR TRIAL

Sponsor

G1 Therapeutics

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology